KRAS SNPs are related to colorectal cancer susceptibility and survival in Chinese people

Papers of special note have been highlighted as: • of interest; •• of considerable interest

References

• 1. Cyhaniuk A, Coombes ME. Longitudinal adherence to colorectal cancer screening guidelines. Am. J. Manag. Care 22(2), 105–111 (2016).
  MedlineGoogle Scholar
• 2. Kendzor DE, Costello TJ, Li Y et al. Race/ethnicity and multiple cancer risk factors among individuals seeking smoking cessation treatment. Cancer Epidemiol. Biomarkers Prev. 17(11), 2937–2945 (2008).
  MedlineGoogle Scholar
• 3. Russo A, Rizzo S, Bronte G et al. The long and winding road to useful predictive factors for anti-EGFR therapy in metastatic It is should colorectal carcinoma: the KRAS/BRAF pathway. Oncology 77(Suppl. 1), 57–68 (2009).
  Medline CASGoogle Scholar
• 4. Dobre M, Dinu DE, Panaitescu E et al. KRAS gene mutations – prognostic factor in colorectal cancer? Rom. J. Morphol. Embryol. 56(Suppl. 2), 671–678 (2015).
  MedlineGoogle Scholar
• 5. Wang Q, Yu X, Li Q et al. Association between miR-199a rs74723057 and MET rs1621 polymorphisms and the risk of hepatocellular carcinoma. Oncotarget 7(48), 79365–79371 (2016). • Effects of KRAS mutation and polymorphism on the risk and prognosis of oral squamous cell carcinoma.
  MedlineGoogle Scholar
• 6. Jazdzewski K, Murray EL, Franssila K et al. Common SNP in premiR-146a decreases mature miR expression and predisposes to papillary thyroid carcinoma. Proc. Natl Acad. Sci. 105(20), 7269–7274 2008).
  Medline CASGoogle Scholar
• 7. Johnson SM, Grosshans H, Shingara J et al. RAS is regulated by the let-7 microRNA family. Cell 120(5), 635–647 (2005). •• It showed us the let-7 microRNA may regulate RAS function and the possible mechanisms.
  Medline CASGoogle Scholar
• 8. Chin LJ, Ratner E, Leng S et al. A SNP in a let-7 microRNA complementary site in the KRAS 3′UTR increases nonsmall cell cancer risk. Cancer Res. 68(20), 8535–8540 (2008). • The SNPs in the miRNA may regulate the KRAS function by binding KRAS 3′UTR.
  Medline CASGoogle Scholar
• 9. Zhang SY, Shi J. rs61764370 polymorphism of KRAS and risk of cancer in Caucasian population: a meta-analysis. J. Cancer Res. Ther. 12(2), 699–704 (2016). • A meta-analysis about rs61764370 polymorphism of KRAS and risk of cancer in Caucasian population.
  Medline CASGoogle Scholar
• 10. Zhao WH, Qu XF, Xing ZG. Association of rs712 polymorphism in KRAS gene 3′-luntranslated region and cancer risk: a meta-analysis. J. BUON 20, 309–316 (2015).
  MedlineGoogle Scholar
• 11. Dai Q, Wei HL, Huang J et al. KRAS polymorphisms are associated with survival of CRC in Chinese population. Tumour Biol. 37(4), 4727–4734 (2016).
  Medline CASGoogle Scholar
• 12. Wang Y, Dong D, Jiang S et al. miR-216b post-transcriptionally downregulates oncogene KRAS and inhibits cell proliferation and invasion in clear cell renal cell carcinoma. Cell. Physiol. Biochem. 49(5), 1755–1765 (2018).
  Medline CASGoogle Scholar
• 13. Bos JL, Fearon ER, Hamilton SR et al. Prevalence of RAS gene mutations in human colorectal cancers. Nature 327(6120), 293–297 (1987).
  Medline CASGoogle Scholar
• 14. Boughdady IS, Kinsella AR, Haboubi NY et al. K-RAS gene mutations in adenomas and carcinomas of the colon. Surg. Oncol. 1(4), 275–282 (1992).
  Medline CASGoogle Scholar
• 15. Ying HQ, Wang F, He BS et al. The involvement of KRAS gene 3′-UTR polymorphisms in risk of cancer and influence on patient response to anti-EGFR therapy in metastatic colorectal cancer: a meta-analysis. Onco Targets Ther. 7, 1487–1496 (2014).
  Medline CASGoogle Scholar
• 16. Deng Y, Wang L, Tan S et al. KRAS as a predictor of poor prognosis and benefit from postoperative FOLFOX chemotherapy in patients with stage II and III colorectal cancer. Mol. Oncol. 9(7), 1341–1347 (2015).
  Medline CASGoogle Scholar
• 17. Lièvre A, Bachet JB, Le Corre D et al. KRAS mutation status is predictive of response to cetuximab therapy in Collector cancer. Cancer Res. 66(8), 3992–3995 (2006).
  Medline CASGoogle Scholar
• 18. Paranjape T, Heneghan H, Lindner R et al. A 3′-untranslated region KRAS variant and triple-negative breast cancer: a case–control and genetic analysis. Lancet Oncol. 12(4), 377–386 (2011).
  Medline CASGoogle Scholar
• 19. Hollestelle A, Pelletier C, Hooning M et al. Prevalence of the variant allele rs61764370 T>G in the 3′UTR of KRAS among Dutch BRCA1, BRCA2 and non-BRCA1/BRCA2 breast cancer families. Breast Cancer Res. Treat. 128(1), 79–84 (2011). • rs61764370 T>G in the 3′UTR of KRAS in the BRCA1/BRCA2 breast cancer families were different.
  MedlineGoogle Scholar
• 20. Ovarian Cancer Association Consortium; Breast Cancer Association Consortium; Consortium of Modifiers of BRCA1 and BRCA2, Hollestelle A et al. No clinical utility of KRAS variant rs61764370 for ovarian or breast cancer. Gynecol. Oncol. 141(2), 386–401 (2016).
  MedlineGoogle Scholar
• 21. Zhang W, Winder T, Ning Y et al. A let-7 microRNA-binding site polymorphism in 3′-untranslated region of KRAS gene predicts response in wild-type KRAS patients with metastatic Collector cancer treated with cetuximab monotherapy. Ann. Oncol. 22(1), 104–109 (2011). • Let-7 miRNA-binding site polymorphism in 3′-untranslated region of KRAS gene predicts response in wild-type KRAS patients with metastatic colorectal cancer.
  Medline CASGoogle Scholar
• 22. Christensen BC, Moyer BJ, Avissar M et al. A let-7 microRNA-binding site polymorphism in the KRAS 3′UTR is associated with reduced survival in oral cancers. Carcinogenesis 30(6), 1003–1007 (2009). • Polymorphism in the KRAS 3′UTR is associated with reduced survival in oral cancers.
  Medline CASGoogle Scholar
• 23. Graziano F, Canestrari E, Loupakis F et al. Genetic modulation of the Let-7 microRNA binding to KRAS 3′-untranslated region and survival of metastatic colorectal cancer patients treated with salvage cetuximab-irinotecan. Pharmacogenomics J. 10(5), 458–464 (2010).
  Medline CASGoogle Scholar
• 24. Jiang QH, Peng HX, Zhang Y et al. rs712 polymorphism within let-7 microRNA-binding site might be involved in the initiation and progression of colorectal cancer in Chinese population. Onco Targets Ther. 8, 3041–3045 (2015).
  Medline CASGoogle Scholar
• 25. Jin H, Liang Y, Wang X et al. Association between a functional polymorphism rs712 within let-7-binding site and risk of papillary thyroid cancer. Med. Oncol. 31(10), 221 (2014). • The functional polymorphism rs712 within let-7-binding may affect the risk of papillary thyroid cancer.
  MedlineGoogle Scholar
• 26. Li ZH, Pan XM, Han BW et al. A let-7 binding site polymorphism rs712 in the KRAS 3′ UTR is associated with an increased risk of gastric cancer. Tumour Biol. 34(5), 3159–3163 (2013).
  Medline CASGoogle Scholar
• 27. Wang WY, Chien YC, Wong YK et al. Effects of KRAS mutation and polymorphism on the risk and prognosis of oral squamous cell carcinoma. Head Neck 34(5), 663–666 (2012).
  MedlineGoogle Scholar
• 28. Crowley EH, Arena S, Lamba S et al. Targeted knock-in of the polymorphism rs61764370 does not affect KRAS expression but reduces let-7 levels. Hum. Mutat. 35(2), 208–214 (2014).
  Medline CASGoogle Scholar
• 29. Ning L, Rao W, Yu Y et al. Association between the KRAS gene polymorphisms and papillary thyroid carcinoma in a Chinese Han population. J. Cancer 7(15), 2420–2426 (2016).
  Medline CASGoogle Scholar
• 30. Friedberg EC, Bond JP, Burns DK et al. Defective nucleotide excision repair in Xpc mutant mice and its association with cancer predisposition. Mutat. Res. 459(2), 99–108 (2000).
  Medline CASGoogle Scholar